Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Sees Significant Decline in Short Interest

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 15,577 shares, a drop of 51.9% from the May 31st total of 32,362 shares. Based on an average daily volume of 23,991 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.8% of the shares of the company are short sold.

Sigyn Therapeutics Price Performance

Shares of Sigyn Therapeutics stock remained flat at $0.04 on Tuesday. The company had a trading volume of 5,247 shares, compared to its average volume of 8,794. Sigyn Therapeutics has a 12-month low of $0.01 and a 12-month high of $5.00. The company has a fifty day simple moving average of $0.04 and a 200 day simple moving average of $0.45. The company has a market capitalization of $93,218.00, a price-to-earnings ratio of -0.01 and a beta of -0.06.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.